Pending Jak verdicts take on great significance

Snippets

More evidence emerged yesterday to suggest that an era of regulatory permissiveness is ending in the US: the FDA seems to be taking a closer look at the safety of the Jak inhibitor class. A delay to new approval decisions for Abbvie's Rinvoq sliced $10bn, or 5%, from the company's market cap; sellside revenue forecasts show that Abbvie potentially has the most to lose here, should toxicity concerns prompt the regulator to try to restrict these drugs' use. With several other regulatory decisions on the Jak class looming, the extent of the FDA's worries should soon become clear. Both of Pfizer's Jaks are awaiting verdicts: a line extension into ankylosing spondylitis for the older Xeljanz and a much more important first approval for the follow-on project abrocitinib in atopic dermatitis. The latter is a disease in which serious safety concerns will not be tolerated, as it is considered less severe than Jak settings like RA. Lilly too has an atopic dermatitis decision pending for Olumiant. Investors should also be considering the broader message: Leerink analysts believe that any phase III project with known controversies should be considered at heightened risk of delay, a complete response letter or restricted labelling. 

Crunch time: regulatory decisions on the horizon for the Jak inhibitor class
Product Company US and EU decisions due
Jyseleca (Jak1)  Galapagos/Gilead  EMA decision in ulcerative colitis due H2 2021
Abrocitinib/PF-04965842 (Jak 1)  Pfizer FDA decision in atopic dermatitis due Apr 27; EMA decision due H2 2021
Rinvoq (Jak 1)  Abbvie Psoriatic arthritis delayed 3mth to late Q2 2021; FDA decisions expected in ankylosing spondylitis in Q2 and atopic dermatitis in Q3, but could also be delayed; EMA atopic dermatitis decision expected Q3 2021
Xeljanz (Jak 1, 2 & 3) Pfizer FDA decision in ankylosing spondylitis expected Q2 2021
Olumiant (Jak 1 & 2)  Lilly  FDA decision in atopic dermatitis due Q2 2021 (based on Q2 2020 submission)
Source: Evaluate Omnium.

Share This Article